Denali Therapeutics Inc.

07/25/2021 | Press release | Distributed by Public on 07/25/2021 09:28

Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)